RECURRENT MULTIPLE MYELOMA
Clinical trials for RECURRENT MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RECURRENT MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat myeloma: drug combo targets resistant cancer
Disease control OngoingThis early-phase trial tests a combination of three drugs (elotuzumab, mezigdomide, and dexamethasone) in 12 adults with multiple myeloma that has come back or stopped responding after prior treatments. The goal is to find a safe dose and see if the combination can control the ca…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Abdullah Khan • Aim: Disease control
Last updated May 17, 2026 05:26 UTC
-
New 4-Drug cocktail shows promise for Tough-to-Treat myeloma
Disease control OngoingThis study tests a combination of four drugs (isatuximab, carfilzomib, pomalidomide, and dexamethasone) in 30 people whose multiple myeloma has returned or stopped responding to earlier treatments. The goal is to see how many patients' tumors shrink or disappear. This is not a cu…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 17, 2026 05:25 UTC
-
New pill combo for tough myeloma cases pulled before starting
Disease control TerminatedThis study was designed to test the safety and best dose of an experimental oral drug called GB1211 (Selvigaltin) when added to standard chemotherapy for people with multiple myeloma that has come back or stopped responding. The drug works by blocking a protein linked to inflamma…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 17, 2026 05:23 UTC
-
New hope for Tough-to-Treat myeloma: drug cocktail shows promise
Disease control OngoingThis study tests a combination of drugs (selinexor, pomalidomide, dexamethasone, and sometimes carfilzomib) in people with multiple myeloma that has returned or no longer responds to standard treatments. The goal is to find the best dose and see how well the combo controls the ca…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 05:09 UTC
-
New drug combo shows promise for Hard-to-Treat multiple myeloma
Disease control OngoingThis early-stage trial tests a new drug called CB-839 HCl combined with two standard treatments (carfilzomib and dexamethasone) for multiple myeloma that has returned or stopped responding to prior therapy. The main goals are to find the safest dose and to see how well the combin…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
Supercharged immune cells take on Hard-to-Treat myeloma
Disease control OngoingThis early-phase trial tests a new treatment for multiple myeloma that has returned or not responded to prior therapies, including BCMA-targeting treatments. The approach combines specially engineered natural killer (NK) cells (called TiNK) with an antibody drug (isatuximab) and …
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Elvira Umyarova • Aim: Disease control
Last updated May 07, 2026 18:43 UTC
-
Gene test trial aims to outsmart advanced cancers
Knowledge-focused OngoingThis study tests whether analyzing the genes of a patient's tumor can help doctors choose a more effective treatment. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to standard therapy are enrolled. The goal is to see if targe…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 17, 2026 05:23 UTC
-
Lab tests aim to match right drug to each myeloma patient
Knowledge-focused OngoingThis study explores whether using lab tests that screen many drugs at once, along with genetic information, can help doctors choose the best treatment for people with multiple myeloma or plasma cell leukemia that has returned or stopped responding to therapy. The goal is to see i…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: NA • Sponsor: University of Washington • Aim: Knowledge-focused
Last updated May 17, 2026 05:06 UTC